Acteoside API Manufacturers

compare suppliers & get competitive offers

teaser-1024x654-1
No suppliers found
Sorry, there are currently no suppliers listed for this ingredient. Hopefully we can help you with other ingredients.
Notify me!
Want to be the first to find out when a supplier for Acteoside is listed?

Join our notification list by following this page.

List your company
Are you a supplier of Acteoside or other APIs and are you looking to list your company on Pharmaoffer?

Click the button below to find out more

Find CDMO
Looking for a CDMO/CMO that can help you with your pharmaceutical needs?

Click the button below to switch over to the contract services area of Pharmaoffer.

Looking for Acteoside API 61276-17-3?

Description:
Here you will find a list of producers, manufacturers and distributors of Acteoside. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
API | Excipient name:
Acteoside 
Synonyms:
 
Cas Number:
61276-17-3 
DrugBank number:
DB12996 
Unique Ingredient Identifier:
3TGX09BD5B

General Description:

Acteoside, identified by CAS number 61276-17-3, is a notable compound with significant therapeutic applications. Acteoside is under investigation in clinical trial NCT02662283 (Validity and Security of Reh-acteoside Therapy for Patients of IgA Nephropathy).

Classification:

Acteoside belongs to the class of organic compounds known as coumaric acids and derivatives. These are aromatic compounds containing Aromatic compounds containing a cinnamic acid moiety (or a derivative thereof) hydroxylated at the C2 (ortho-), C3 (meta-), or C4 (para-) carbon atom of the benzene ring, classified under the direct parent group Coumaric acids and derivatives. This compound is a part of the Organic compounds, falling under the Phenylpropanoids and polyketides superclass, and categorized within the Cinnamic acids and derivatives class, specifically within the Hydroxycinnamic acids and derivatives subclass.

Categories:

Acteoside is categorized under the following therapeutic classes: Anti-Infective Agents, Antineoplastic Agents, Antineoplastic Agents, Phytogenic, Antioxidants, Benzene Derivatives, Biological Factors, Carbohydrates, Chelating Agents, Compounds used in a research, industrial, or household setting, Glycosides, Immunologic Factors, Immunosuppressive Agents, Protective Agents, Sequestering Agents, Verbenaceae. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.

Acteoside is a type of Anti-infective Agents


Anti-infective agents are a vital category of pharmaceutical active pharmaceutical ingredients (APIs) used in the treatment of various infectious diseases. These agents play a crucial role in combating bacterial, viral, fungal, and parasitic infections. The demand for effective anti-infective APIs has grown significantly due to the increasing prevalence of drug-resistant microorganisms.

Anti-infective APIs encompass a wide range of substances, including antibiotics, antivirals, antifungals, and antiparasitics. Antibiotics are particularly important in fighting bacterial infections and are further categorized into different classes based on their mode of action and target bacteria. Antivirals are designed to inhibit viral replication and are essential in the treatment of viral infections such as influenza and HIV. Antifungals combat fungal infections, while antiparasitics are used to eliminate parasites that cause diseases like malaria and helminthiasis.

The development and production of high-quality anti-infective APIs require stringent manufacturing processes and adherence to regulatory standards. Pharmaceutical companies invest heavily in research and development to discover new and more effective anti-infective agents. Additionally, ensuring the safety, efficacy, and stability of these APIs is of utmost importance.

The global market for anti-infective APIs is driven by factors such as the rising incidence of infectious diseases, the emergence of new and drug-resistant pathogens, and the growing demand for improved healthcare infrastructure. Continuous advancements in pharmaceutical technology and the development of innovative drug delivery systems further contribute to the expansion of this market.

In conclusion, anti-infective agents are a critical category of pharmaceutical APIs that play a pivotal role in treating infectious diseases. Their effectiveness in combating various types of infections makes them essential components in the arsenal of modern medicine.